Fig. 2.

a Mean change in central retinal thickness within 1 mm of the fovea (CFT) over the course of 2 years of aflibercept treatment for all participants and according to baseline BCVA. b Mean change in central subfoveal volume within 6 mm of the fovea (CSVol) over the course of 2 years of aflibercept treatment, for all participants and according to baseline BCVA. CFT was measured by spectral domain-optical coherence tomography (Heidelberg Spectralis; Heidelberg Engineering Inc., Heidelberg, Germany). CFT and CSVol adjusted for repeated measures, patient age, sex, baseline glycosylated hemoglobin, and previous laser therapy. Error bars indicate the SD